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ADCC, antibody-dependent cell-dependent cytotoxicity; α-Gal, galactose-α-1,3-galactose; 
BP, breakpoints; CEMIP, cell migration inducing hyaluronan binding protein gene; ddPCR, 
droplet digital polymerase chain reaction; EC50, half maximal effective concentration; 
EGFR, epidermal growth factor receptor; Gal, galactose; gCetuximab, goat-produced 
cetuximab; gCSN2, goat β-casein gene; GFF, goat fetal fibroblast; HC, heavy chain; IL-2, 
interleukin-2; LC, light chain; LGB, beta-lactoglobulin gene; mAb, monoclonal antibody; 
MFI, mean fluorescent intensity; PGK, 3-phosphoglycerate kinase; REF, integrative genome 
viewer; SCNT, somatic cell nuclear transfer; WT, wild type; ZNF451, zinc finger protein 451 
gene 
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Therapeutic monoclonal antibodies (mAbs) represent one of the most important classes of 
pharmaceutical proteins to treat human diseases. Most are produced in cultured mammalian 
cells which is expensive, limiting their availability. Goats, striking a good balance between a 
relatively short generation time and copious milk yield, present an alternative platform for the 
cost-effective, flexible, large-scale production of therapeutic mAbs. Here, we focused on 
cetuximab, a mAb against epidermal growth factor receptor, that is commercially produced 
under the brand name Erbitux and approved for anti-cancer treatments. We generated several 
transgenic goat lines that produce cetuximab in their milk. Two lines were selected for 
detailed characterization. Both showed stable genotypes and cetuximab production levels of 
up to 10g/L. The mAb could be readily purified and showed improved characteristics 
compared to Erbitux. The goat-produced cetuximab (gCetuximab) lacked a highly 
immunogenic epitope that is part of Erbitux. Moreover, it showed enhanced binding to CD16 
and increased antibody-dependent cell-dependent cytotoxicity compared to Erbitux. This 
indicates that these goats produce an improved cetuximab version with the potential for 
enhanced effectiveness and better safety profile compared to treatments with Erbitux. In 
addition, our study validates transgenic goats as an excellent platform for large-scale 




Monoclonal antibody, biosimilar, EGFR, biobetter,  
  
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a




Monoclonal antibodies (mAbs) represent an important class of biopharmaceutical drugs for 
the treatment of serious human diseases, with many ranked within the ten top-selling 
biopharmaceuticals (1). They are commonly produced as recombinant proteins in cultured 
mammalian cells to ensure proper glycosylation which is often required for full functionality 
and makes it currently the prevailing and most accepted production system (2, 3). Still, high 
up-front capital investment for the production facilities and lack of scalability are recognized 
weaknesses of this technology (4, 5). Dairy animals and production of recombinant 
therapeutic proteins in milk could provide an attractive alternative production platform for the 
large-scale manufacture of valuable human drugs based on the mammary gland’s high protein 
production capacity, easy access to the recombinant proteins in milk, great scalability and 
cost effectiveness (6). The concept for such an animal-based production system has already 
been fully validated with the approval of three proteins isolated from milk. Recombinant 
forms of human antithrombin produced in the milk of goats, as well as C1 esterase inhibitor 
and coagulation factor VII produced in the milk of rabbit,s are all being commercialized as 
therapeutics for the treatment of human diseases (7-11). Moreover, the potential for mass 
production of a therapeutic antibody was exemplified in a recent study reporting production 
of an anti-CD20 antibody in the milk of cattle (12). 
 
Cetuximab is a chimeric mouse-human mAb, targeting the epidermal growth factor receptor 
(EGFR), that has approval for the treatment of metastatic colorectal and head and neck 
cancers (13). The approved mAb is produced in the mouse-derived cell line SP2/0 and is 
marketed under the brand name Erbitux. In 2014 it was the 19th biggest-selling drug 
worldwide, with annual sales of US$1.9 billion (1). However, the murine SP2/0 production 
cell line of commercial Erbitux modifies the variable region of the heavy chain with a 
galactose-α-1,3-galactose (α-Gal) at an N-linked glycosylation (14, 15). This glycan structure 
is not found in humans and has been shown to be associated with adverse effects in patients 
treated with Erbitux (14). 
 
Here, we describe the development and characterisation of two transgenic goat lines to 
produce cetuximab in milk. We demonstrated trans-generational stability of the integrated 
transgenes and cetuximab production at levels up to 15 g/L of milk. gCetuximab was lacking 
the problematic α-Gal glycosylation and showed enhanced antibody-dependent cell-
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dependent cytotoxicity (ADCC) compared to commercial Erbitux, both hallmarks for the 
production of an improved cetuximab version. 
 
MATERIALS AND METHODS 
All experiments were performed in accordance with the relevant guidelines and regulations 
with approvals from New Zealand’s Environmental Protection Authority and the Ruakura 
Animal Ethics Committee.  
 
Generation of Expression Vectors 
Cetuximab light and heavy chain coding sequences were optimized and synthesized by 
Geneart AG, now a part of Thermo Fisher Scientific of Waltham, MA, USA. Two separate 
expression constructs were made to target expression of both the light and heavy chains of 
cetuximab to the lactating mammary gland. Both constructs were based on the expression 
vector Bc450, which contains an expression cassette consisting of two copies of a fragment 
of DNA isolated from the 5’ end of the chicken B-globin locus, which is predicted to reduce 
positional effects by directionally inducing transcriptionally active decondensed regions in 
chromatin (16), 5’ (6.2 kb ) and 3’ (7.1 kb) goat β-casein gene (gCSN2) sequences flanking 
an XhoI cloning site that direct expression to the mammary gland, in a Supercos backbone. 
To generate the vector Bc2553, the cetuximab light chain was cloned into the XhoI site of a 
derivative of the expression vector Bc450 (Figure S1A).  
 
The heavy chain expression vector Bc2584 was constructed by ligating three fragments of 
DNA (Figure S1B,C). The first step was to generate an intermediate construct by inserting 
the heavy chain coding sequence into Bc350, which is identical to Bc450 described above 
except for the replacement of the downstream SalI site with a NotI restriction site. Following 
excision of the heavy chain expression fragment with SalI and NotI, it was ligated in a second 
step with a 1.5 kb SalI/NotI fragment containing the puromycin resistance gene (17) and a 
SalI/SalI Supercos vector backbone fragment in a three-way reaction.  
 
Cell culture and cell clone isolation 
Female primary goat fetal fibroblasts (GFFs) were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM)/F12 with non-essential amino acids, 10% FCS and human fibroblast 
growth factor-2 (5 ng/mL, Sigma-Aldrich, St Louis, MO, USA) at 37 °C. GFFs were co-
transfected with 3 µg of a 16.4 kb SalI fragment excised from the expression construct for the 
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cetuximab light chain (LC) and 1.7 µg of a 18.7 kb SalI fragment for the heavy chain (HC) 
by nucleofection using the Basic Nucleofector Kit for Primary Mammalian Fibroblasts with 
programme A-24 according to the manufacturer’s instructions (Lonza, Cologne, Germany). 
Cell clones were isolated after approximately 12 days of puromycin selection (1.5 µg/mL), 
initially transferred individually into 96-well plates before transfer to larger multi-well 
formats for further expansion.  
 
Somatic cell nuclear transfer (SCNT) 
In vivo ovulated oocytes were surgically flushed from synchronised donors and enucleated 
under minimal ultraviolet light exposure following staining with 2 µg/mL Hoechst 33342 
(Sigma-Aldrich, St. Louis, MO, USA) for 2 min. Prior to SCNT, transgenic donor cells were 
serum starved for 4-6 days and then re-stimulated with medium containing 10% FCS 
approximately 4 h before fusion. Individual donor cells were fused with enucleated oocytes 
and simultaneously activated by two direct current electric pulses (2 kV/cm for 10 µs each) in 
fusion buffer containing 50 µM calcium. Approximately 45 min following successful fusion, 
reconstructed embryos were given either a second electrical treatment as above or were 
exposed to 2.5 µM ionomycin for 1 min to further stimulate activation. For the next 3 h, the 
SCNT embryos were cultured in cycloheximide (5 µg/mL) and cytochalasin B (5 µg/mL) and 
then cultured overnight in AgResearch SOF media. Resulting 1- and 2-cell embryos were 
surgically transferred to the oviducts of recipients two days after oestrus, at a range of 5-11 
embryos/recipient. Pregnant goats were identified by ultrasound 30 days after transfer and 
monitored regularly thereafter. Parturition was induced for a planned delivery five days 
before expected full term by administering a combination of prostaglandin and 
dexamethasone 36 h beforehand. 
 
Genotype analyses 
DNA was isolated from cell and blood samples using a Nucleon BACC2 kit (Cytiva, Little 
Chalfont, UK).  Cell clones were analysed by PCR amplification of LC- and HC-specific 
amplicons. Insertion of the LC-transgene was determined with PCR primers GL560 and 
GL561. The HC-specific fragment (449 bp) was amplified with primer pair GL556/GL573. 
Amplification of a gCSN2 fragment (198 bp) with primer pair GL579/580 served as positive 
control. The PCR amplification for each gene sequence was performed with 50 ng of 
genomic DNA in a 20 µL reaction using a KAPA Taq PCR Kit (Sigma-Aldrich, St Louis, 
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MO, USA) and the following cycle conditions: one pre-cycle step 3 min at 95°C, 38 cycles of 
15 s at 95°C, 15s at 60°C, 1 s at 72°C and a final step of 5 min at 72°C.  
Confirmation of the endogenous to transgene sequence junctions were confirmed by PCR 
with primer pairs GL1313/GL1314 (BP1, GN388), GL1258/GL1256 (BP2, GN388) and 
GL1309/GL1312 (BP1, GN451). PCR conditions were as above except for a longer extension 
step of 5 s.  
For ddPCR quantitation of cetuximab LC transgenes, 25 ng of genomic DNA were amplified 
with LC-specific primers GL1459/GL1460 and goat beta-lactoglobulin gene (LGB) primers 
GL1470/GL1471 as reference, in the presence of the LC target FAM probe GL1468 and 
reference HEX probe GL1472 in a 22 µL reaction. The probes were double-quenched with an 
internal ZEN quencher and 3’ IBFQ quencher (Integrated DNA Technologies, Coralville, IA, 
USA). Following droplet generation with a QX200 system (Bio-Rad), the DNA was 
denatured for 10 min at 95°C and amplified in each droplet by 40 cycles of 30 s at 94°C, 1 
min at 60°C with a ramping rate of 2°C/s and a final step of 10 min at 98°C. Fluorescence of 
individual droplets was determined with the QX200 droplet reader and transgene copy 
number quantified using the QuantaSoft Analysis Pro software (Bio-Rad, Hercules, CA, 
USA). The copy number analysis was done with three technical replicates for each sample. 
The quantitation of the HC transgenes was performed the same way but used HC-specific 
primers (GL1457/GL1458) and probe (GL1467) instead of the LC-specific ones.  
All PCR primer and fluorescent hybridisation probe sequences are listed in Table 1. 
For Southern analyses, 5 µg of genomic DNA was digested with EcoRI, transferred to 
membrane and hybridized with a radioactively-labelled 660 bp XhoI/HindIII fragment, 
spanning parts of exon 7 and exon 8 of gCSN2, for the detection of LC- and HC-transgenes as 
well as the endogenous gCSN2 fragments. Hybridization signals were determined by X-ray 
film densitometry (GS-800, Bio-Rad, Hercules, CA, USA) and transgene copy numbers 
quantified with normalization against the two endogenous gCSN2 copies using Quantity One 
software (Bio-Rad, Hercules, CA, USA). 
 
Table 1. Summary of PCR primers and probes.   
ID Use Gene Sequence Amplicon 
GL560 PCR primer Light Chain GAGCAGGACAGCAAGGACTC 156 bp 
GL561 PCR primer Light Chain CTATCAGCACTCGCCCCTG  
GL556 PCR primer Heavy Chain GGAAGCATGGAGTCTTGGAC 449 bp 
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GL573 PCR primer Heavy Chain GAAGAACACCTGGCTCTTGC  
GL579 PCR primer Goat CSN2 CCACAAAACATCCTGCCTCT 198 bp 
GL580 PCR primer Goat CSN2 AGGAAGGTGCAGCTTTTCAA  
GL1309 PCR primer Goat CEMIP GCAGGGTGGCCTTTGAAATG 608bp 
GL1312 PCR primer Puromycin CCACTCCCACTGTCCTTTCC  
GL1313 PCR primer Goat ZN451 TCCCCCTTCTCGCCTCATTA 487 bp 
GL1314 PCR primer Goat CSN2 TTGGCTTGCATGTGTGTGTG  
GL1258 PCR primer Puromycin TCTGAGCCCAGAAAGCGAAG 1594 bp 
GL1256 PCR primer Goat ZN451 GTACCAGTGCAAGAGGGCTT  
GL1459 ddPCR primer Light Chain TCGTGTTCCTGCTGTTCTG 81 bp 
GL1460 ddPCR primer Light Chain GAGACACGCTCAGGATCAC  
GL1457 ddPCR primer Heavy Chain AGTTCCGGACTGTATTCCCT 82 bp 
GL1458 ddPCR primer Heavy Chain TCACGTTGCAGATGTAGGTC  
GL1470 ddPCR primer Goat LGB AAGGAGGCCCTGGAGAAATT 80 bp 
GL1471 ddPCR primer Goat LGB AGCTGGGTCGGGTTGAA  
GL1468 FAM probe Light Chain CGACATCCTGCTGACCCAGA NA 
GL1467 FAM probe Heavy Chain TGTCGTGACAGTCCCTTCCT NA 
GL1472 HEX probe Goat LGB CCCTGTTTATGCACATCC NA 
 
Whole genome next generation sequencing 
To locate and enumerate the transgenes, Illumina Next Generation sequencing was employed. 
Two libraries, Nextera mate pair (5kb) and Illumina PCR-free paired end (550bp), were made 
from a single GN388 and GN451 founder goat. The resulting fastq files were checked for low 
quality regions and adapters using fastqc version 0.11.5 (18). These regions were trimmed 
using trimmomatic version 0.3.6 (19). The trimmed reads were then mapped to the combined 
sequences of the two transgenes and Caprine Genome Assembly ASM170441 version 1 (20), 
using the “MEM” algorithm of BWA version 0.7.9a-r786 (21) with the resulting output being 
converted into BAM file and indexed using samtools version 1.3 (22). To locate the 
transgenes, the resulting output was searched for read pairs where each read mapped to a 
different chromosome or one read mapped to one of the transgene sequences and the other 
mapped to a chromosome. A single distinct location appeared for each of the two sequenced 
goats. This was checked and confirmed using the integrative genome viewer (23). The copy 
numbers of both transgenes were enumerated by comparing the average coverage of gCSN2 
and the average coverage of all and specific regions of the genome as calculated from the 
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output of the “depth” function of samtools (22) selecting only sequenced bases with a quality 
value of at least 30 from sequencing reads with a mapping quality of at least 30. To 
enumerate copies of the LC- and HC-transgenes and ensure their integrity, the mapping of the 
reads across the unique regions encoding cetuximab light and heavy chains and not shared 
between transgene or endogenous host genome, was enumerated using the “depth” function 
of samtools and examined in Integrative Genomic Viewer for possible mutations. The overall 
copy number for both transgenes was enumerated by comparing the average coverage of the 
5’ and 3’ gCSN2 regulatory sequences (CM004567.1, position 86,000,517-86,007,945 and 
86,013,215-86,019,039, respectively), shared by the genome and the transgenes, and the 
average coverage of all regions of the genome as calculated from the output of the “depth” 
function of samtools (22). In addition, we also determined the coverage across the CNS2 
region which encompassed the coding information unique to the genome and not part of the 
transgenes (CM004567.1, position 86,007,946-86,013,214). The coverage per haploid 
genome was calculated by dividing the average coverage of all regions of the genome by two. 
To calculate the copy number of the transgenes and the endogenous gCSN2 genes, the 
average coverage of the sequencing reads over the relevant regions was calculated and 
divided by the coverage per haploid genome. To enumerate copies of the LC- and HC-
transgenes we used coverage for the transgene specific regions encoding the LC- and HC-
chain which is not shared between transgene or endogenous host genome for the calculation. 
To ensure the integrity of the transgenes, the mapping of the sequence reads across the unique 
LC- and HC-regions was examined using Integrative Genomic Viewer for possible mutations 
and gaps in coverage.  
 
Induced lactation and milk analysis 
At the age of 3-6 months, goats were hormonally induced into lactation as described 
previously (24). Briefly, every other day goats were given intramuscular injections of 
estrogen (0.25 mg/kg live weight) and progesterone (0.75 mg/kg live weight) for a total of 
seven treatments. For the following three days, goats received daily intramuscular injections 
of dexamethasone (0.3 mg/kg live weight). From the third estrogen/progesterone injection 
onwards, the mammary glands were manually massaged daily to stimulate lactogenesis and 
milk secretion was expected to begin at the end of the estrogen/progesterone treatment or 
with the dexamethasone injections. Once milk secretion had started, the goats were hand 
milked once a day and milk collected for up to 30 days. 
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For access to natural lactation milk, goats were either naturally mated or artificially 
inseminated. Following kidding, goats were milked twice daily with am and pm milk pooled 
to generate daily milk samples for analysis. 
Milk proteins were separated by SDS PAGE on Criterion TGX 4-20% gels (Bio-Rad). 
Following wet transfer onto a Hybond ECL membrane (Cytiva, Little Chalfont, UK), 
expressed gCetuximab light- and heavy-chains were detected with a peroxidase-conjugated 
anti-human IgG antibody (MP Biomedicals, Santa Ana, USA) and visualized with Bio-Rad 
Clarity™ Western ECL Substrate (Bio-Rad, Hercules, CA, USA). Chemiluminescence was 
detected with an ImageQuant Las 4000 instrument (Cytiva, Little Chalfont, UK) and 
quantified using Bio-Rad Quantity One software (Bio-Rad, Hercules, CA, USA). For a 
reference standard we used an in-house produced monoclonal antibody of known 
concentration.  
 
Quantitation of Induced and Natural Lactation Milk Samples 
Milk proteins were separated by SDS-PAGE on NuPage 4-12% Bis-Tris gels (Invitrogen, 
Carlsbad, CA, USA) electrophoresed in MOPS buffer and transferred to nitrocellulose 
membranes (Whatman, Little Chalfont, UK) in NuPage transfer buffer. Expressed cetuximab 
light- and heavy-chains were detected with an IR800-affinity purified goat anti-human IgG 
(H+L) (Rockland 609-132-123, Rockland Immunochemicals, Limerick, PA ,USA) in Licor 
Blocking buffer and visualized on a Licor Odyssey Imaging System. Estimates of cetuximab 
concentration were made by visual comparison to standard antibody of known concentration. 
Estimates of concentration were also made by comparison of the yield of purified antibody to 
the starting volume of milk, adjusted for normal losses in purification. 
 
Purification of gCetuximab 
Frozen milk samples were defrosted, and volumes of 25 mL and 100 mL of transgenic goat 
milk were processed for purification of gCetuximab. Milk samples were diluted 1:1 with PBS 
followed by centrifugation at 10,000 to 12,000 x g for 60 min at 4˚C. The resulting clarified 
milk fraction was filtered through a 2.7 µm or 5 µm depth filter and stored frozen prior to 
commencing with the isolation of gCetuximab by column chromatography. For this next step, 
the clarified milk was thawed and loaded at 150 cm/h and 90 cm/h onto a 22 mL (1.6 x 11 
cm) and 40 mL (1.6 x 20 cm) rPA Sepharose FF (GE Healthcare, Uppsala, Sweden) Protein 
A affinity chromatography column equilibrated with PBS for samples with a 25 mL and 100 
mL milk starting volume, respectively. The column was washed with PBS followed by 100 
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mM acetate pH5.5 buffer containing 500 mM sodium chloride and gCetuximab eluted with 
100 mM glycine pH3.0 buffer. The eluted fraction was neutralized with 2 M Tris pH7.0 and 
either diluted first 1:1 with 20 mM phosphate pH7.0 buffer (25 mL milk sample) or loaded 
directly (100 mL milk sample) onto a Q Sepharose FF (GE Healthcare, Uppsala, Sweden) 
equilibrated with 20 mM phosphate pH7.2 buffer column at 150 cm/h and 90 cm/h, 
respectively. gCetuximab was collected in the flow-through fraction and diafiltered against 5 
diavolumes of PBS using 0.04 m2 of 30 kDa MWCO PES membrane (Novasep, Shrewsbury, 
MA, USA). Samples were quantified spectrophotometrically by absorbance at 280 nm using 
a general extinction coefficient of 1.4. 
 
gCetuximab glycosylation analysis 
Milk samples were obtained and the gCetuximab purified as described above. Samples were 
analyzed by contract with Glycan Connections LLC (Lee, NH, USA) using LC/MS 
methodology to determine the glycosylation patterns. The percent of each of the resulting 
patterns were tabulated.  
Relative galactosylation refers to the sum of the percentage of each carbohydrate structure 
found in the sample multiplied by the number of Gal residues in that structure, which can be 
zero, one, or two.  For example, if a fully sialated complex structure (2 gals) were present at 
15% of the carbohydrate structure population, it’s contribution to relative galactosylation 
would be 2 x 15 = 30. A similar hybrid structure with one Gal would contribute 1 x 15 = 15 
to the relative galactosylation. By this method the maximum relative galactosylation could be 
2 x 100% or 200.   
Dividing this value by 2 gives the percentage of the maximum potential galactosylation in the 
sample.   
Any given molecule contains four N-linked carbohydrate structures - two on the heavy chain 
constant regions and two on the heavy chain variable regions. Additionally, each 
carbohydrate structure can have one or two Gal residues, so the maximum number of Gal per 
molecule is eight. Multiplying the percentage galactosylation times eight gives the average 
number of Gal/mole of the sample.  
 
Western blot to determine presence of alpha 1,3 galactose  
Western blot analysis was carried out using standard procedures for SDS-PAGE 
electrophoresis on 4-12% NuPage gels in MOPS buffer (Invitrogen, Carlsbad, CA, USA), 
then transferred to nitrocellulose membranes (Whatman, Little Chalfont, UK) in NuPage 
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Transfer buffer. The detecting antibody used was a mouse IgM to alpha 1,3 gal (ALX-801-
090, Enzo Life Sciences, Farmingdale, NY, USA). The secondary antibody was HRP goat 
anti-mouse (SC2064, Santa Cruz Biotechnology, Dallas, TX, USA), followed by 
visualization with ECL Western Blot Detection Reagent (Amersham, Little Chalfont, UK) on 
X-ray film. 
HPLC assay for α-Gal was performed by treating 50mg of protein in 50mM Sodium Acetate 
pH5.0 with and without α-galactosidase A (Fabrazyme, Sanofi Genzyme, Cambridge, MA, 
USA). The released α-Gal was collected in a Millipore 5K MWCO spin filter and labelled 
with 2-aminobenzoic acid (2AA), then analyzed by HPLC on a Waters Symmetry C18 
column. 
 
Binding to EGFR 
Binding to EGFR was evaluated with an assay to show binding to HTB-30 cells, a human 
breast cancer cell line expressing EGFR. Briefly, cells were washed with PBS and counted. 
1x106 cells were aliquoted and mixed with antibody samples at various concentrations, then 
incubated on ice for 30 min. Cells were again washed with PBS to remove unbound primary 
antibody and incubated with goat anti-human IgG conjugated to FITC (Southern 
Biotechnology Associates, Birmingham, AL, USA) for 30 min on ice. Cells were again 
washed and fixed with 1% paraformaldehyde, diluted to a concentration of 1x105 cells/mL, 
and fluorescence determined on a Guava flow cytometer (Merck Millipore, Darmstadt, 
Germany). The mean fluorescence intensity (MFI) was plotted against antibody concentration 
to show binding efficiency. 
 
Binding to CD16 
Binding to CD16 was studied by a competitive assay with an anti-CD16-PE/3G8 antibody 
conjugated to phycoerythrin (Beckman Coulter, Brea, CA, USA) and unlabelled test and 
control antibodies using Jurkat-CD16 cells. 
In V bottom 96 well plates, 2x105 cells/well (50 µL of cells at 4x106 cell/mL) were incubated 
20 min at 4°C with a final concentration of 333 µg/mL of the tested molecules diluted in PBS, 
simultaneously with anti-CD16-PE/3G8 conjugate diluted at 1/10, a fixed concentration. Cells 
were washed by adding 100 µL PBS and centrifuged at 1700 rpm for 3 min at 4°C. Supernatant 
was removed and 300 µL cold PBS was added. Binding of anti-CD16-PE/3G8 to CD16 
expressed by Jurkat-CD16 cells was evaluated by flow cytometry. Relative CD16 binding is 
expressed in percent; 100% being the MFI obtained with the R297 anti-D mAb (LFB, Les Ulis, 
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France) and 0% the MFI measured in the presence of Rituxan (commercial). Antibody R297, 
produced in YB2/0 cells, is used as an example of a low fucose antibody with high affinity for 
CD16, while Rituxan, produced in CHO cells, has significantly lower affinity for CD16, 
providing high and low binding examples used as arbitrary 100% and 0% standards. (Data not 
shown.) 
 
Presence of EGFR on Hep-2 Cells for Use in Activation Assay 
EGFR expression in Hep-2 cells was confirmed by flow cytometry. Briefly, Hep-2 cells and 
antibodies were diluted in diluent (PBS with 1% FCS) and 1 x 105 cells were incubated with 
100 µL of Erbitux at 10 and 50 µg/mL (final concentration) at 4°C for 30 min. 
After washing in diluent, bound antibodies were visualized using 100 µL of a 1:100 dilution of 
goat F(ab’)2 anti-human IgG coupled to phycoerythrin (Beckman Coulter, Brea, CA, USA) at 
4°C for 30 min. The cells were washed and MFI was quantified by flow cytometry (FC500, 
Beckman Coulter, Brea, CA, USA).  
 
Jurkat-CD16 activation assay 
Hep-2 target cells were incubated with increasing concentrations of anti-EGFR antibodies (0 
to 500 ng/mL) in the presence of Jurkat CD16 cells and the protein kinase C activator phorbol-
myristate acetate (P8139, Sigma-Aldrich, St Louis, MO, USA). After 16 h of incubation at 
37°C, the quantity of IL-2 released by Jurkat-CD16 cells was measured in the cell supernatant 
by colorimetry using a human IL-2 DuoSet ELISA DY202-05 Kit (R&D Systems, 
Minneapolis, MN, USA). 
 
RESULTS 
Generation of gCetuximab-producing goats  
Female goat fetal fibroblast (GFF) primary cell lines were co-transfected with two separate 
constructs for the mammary gland-specific expression of the light chain (LC) and heavy 
chain (HC) of cetuximab (Figure 1A).  
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Fig. 1. gCetuximab expression construct outline and detection. A) Schematic of the 
transgenes encoding the cetuximab light chain (LC) and heavy chain (HC) under control of 
the 5’ (dark blue) and 3’ (light blue) gCSN2 regulatory sequences used for the co-transfection 
of primary fetal goat cells. The blue boxes depict exons 1, 8, 9 and partial exons 2 and 7 of 
gCSN2 that flank the LC and HC coding regions. The transgenes also included tandem 
chicken β-globin insulators (black arrows) and at the 3’ end of the HC-transgene an antibiotic 
selection marker (Puro) driven by the 3-phosphoglycerate kinase (PGK) promoter. The 
position of primers used for PCR genotyping and the Southern hybrydisation probe (black 
bar) are indicated. B) Southern analysis of transgenic cell clones. Depicted are the resulting 
hybridisation signals of genomic DNA from a selection of different cell clones probed with a 
gCSN2 fragment. CN: signal from the endogenous gCSN2 copies; HC: signal of the heavy 
chain encoding transgene; LC: signal of the light chain encoding transgene; WT: non-
transgenic wild type control; WT+5/10: wild type genomic DNA spiked with the equivalent 
of 5/10 transgene copies.  
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From two independent transfection campaigns performed within the laboratory over two 
distinct time periods, we isolated a total of 23 cell clones that were confirmed with stable 
integration for both of the transgenes identified by PCR. The number of LC- and HC-
transgene copies was determined by Southern analysis, revealing a wide range in copy 
numbers across the individual cell clones (Figure 1B, Table S1).  
 
We selected nine primary cell clones, representing low, medium and high transgene copy 
numbers that were used as donor cells to generate founder goats by somatic cell nuclear 
transfer (SCNT). Transgenic female kids were born from all nine cell clones. Overall 
efficiency for the production of live kids per total number of transferred embryos for the 
different cell clones ranged between 1% and 8% (on a per embryo transfer basis of 
calculation) to term as well as to weaning (Table 2).  
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Table 2. Summary of nuclear transfer results. 
TG Line Embryos transferred 
(# of recipients)a 
Day 30 of gestation 
(# of recipients)b 
Day 100 of gestation 
(# of recipients)b 
Development 
to term (%)c 
Development 
to weaning (%)c 
GL6.7 56 (8) 2 (2) 2 (2) 2 (4) 2 (4) 
GL6.7 57 (10) 11 (5) 5 (3) 2 (4) 1 (2) 
GL8.3 54 (10) 5 (3) 4 (3) 4 (7) 4 (7) 
GN97 25 (5) 1 (1) 0 (0) 0 (0) 0 (0) 
GN97 48 (7) 1 (1) 2 (1) 2 (4) 1 (2) 
GN97 45 (8) 3 (3) 3 (2) 2 (4) 2 (4) 
GN99 26 (6) 3 (2) 2 (1) 2 (8) 2 (8) 
GN100 77 (10) 5 (4) 5 (4) 4 (5) 3 (4) 
GN118 100 (12) 1 (1) 1 (1) 1 (1) 1 (1) 
GN304 24 (5) 1 (1) *Day 49 1 (1) 1 (4) 1 (4) 
GN388 25 (4) 1 (1) 0 (0) 0 (0) 0 (0) 
GN388 35 (7) 2 (2) *Day 52 2 (2) 2 (6) 2 (6) 
GN451 37 (7) 4 (3) 4 (3) 3 (8) 1 (3) 
a Total number of 1- 2-cell embryos transferred to the total number of recipients given in brackets.  
b Total number of fetuses detected by ultrasound scanning at the indicated time of gestation (* alternative gestational age examined). The values 
in brackets indicate the number of pregnant recipients.  
c Total number of live goats at term or weaning (approximately 3 months) and percentage of total number of transferred embryos that develop 
into live goats in brackets. 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 10, 2020. . https://doi.org/10.1101/2020.06.05.137463doi: bioRxiv preprint 
17 
 
Most of the kids were born as singletons (17 kids) while four sets of twins were also produced. Although most 
kids were strong and healthy after birth, five kids died within the first five days. This included one singleton 
that suffered complications from milk bloat and another singleton as well as three twin kids that were relatively 
small and weak when they were born. PCR analysis was used to confirm the genotype of all founder kids which 
demonstrated the presence of the light chain and heavy chain transgenes (Figure S2).  
 
To determine whether the different transgenic lines expressed gCetuximab in their milk, the founders for the 
nine transgenic lines were hormonally induced into lactation and milked for up to 30 days. The two transgenic 
lines with very high numbers for both LC and HC transgene copies (GL8.3 and GN118) failed to lactate. The 
cloned founder goats from the GL8.3 line only secreted a single drop of a highly viscous substance. Similarly, 
the cloned founder goats from the GN118 line only produced secretions over three days that ranged from a 
maximum of 1 mL to a few drops of viscous material and failed to properly lactate. These lines were not further 
considered for gCetuximab production. The three transgenic lines GN97, GN99 and GN100 with medium 
(GN97) to high (GN99, GN100) LC transgene copy numbers and low HC transgene copy numbers produced 
milk secretions for at least nine days (Figure 2A). However, they were unable to maintain the lactation over 
time and the milk yields dropped over a relatively short period, until milk secretion stopped after nine to 25 
days, depending on the transgenic line and individual animal. In contrast, low transgene copy lines GN304, 
GN451 and GN388 maintained lactation and increased in yield with progression of lactation. The milk 
production levels were markedly higher for both founder goats from line GN388 (maximum of 270 mL and 100 
mL per day, respectively) compared to lines GN304 and GN451 (maximum of 23 mL and 22 mL per day, 
respectively). Founders from the GL6.7 line that were hormonally induced to come into lactation were only 
milked for one day to confirm expression and not assessed for milk yields over several weeks.  
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Fig. 2. Milk and gCetuximab production by founder goats from a hormonally induced lactation. A) Daily milk 
yields for individual founder goats for the medium copy number transgenic lines GN97, GN99 and GN100 (left 
panel), for the founder goats of the low transgene copy number lines GN304 and GN451 (center panel) and 
founders of the low transgene copy number line GN388 (right panel). B) gCetuximab expression in milk. 
Western results of induced milk samples, produced by goats of the indicated transgenic lines, probed with an 
anti-human IgG antibody detecting gCetuximab light- (LC) and heavy-chain (HC). hPlasma: milk sample 
spiked with human plasma; -ve control: milk sample, not containing gCetuximab; +ve control: milk sample 
known to contain gCetuximab; standard: monoclonal antibody at 15 µg/µL. 
 
Milk samples were analyzed by western blotting to detect and determine the level of gCetuximab expression. 
This analysis revealed that the founder transgenic line GL6.7 only expressed the gCetuximab heavy chain 
whereas line GN304 failed to express either of the gCetuximab chains (Figure 2B). The remaining five founder 
transgenic lines (GN97, GN99, GN100, GN388, GN451) expressed both transgenes with gCetuximab 
expression levels ranging from approximately 5 g/L to 15 g/L (Figure 2B, Table 3). Based on the hormonal 
induced lactation profiles and gCetuximab expression levels, two primary founder transgenic lines were 
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selected (GN388 and GN451) for further characterization and moving forward into developmental use in 
subsequent experiments. 
 
Table 3. gCetuximab expression levels in different transgenic goat lines. 
Line gCetuximab expression in milk 
GL6.7 Good HC expression but no expression of LC  
GL8.3 Failed to lactate 
GN97 Unequal expression (low HC, high LC) 
GN99 ~ 15 g/L 
GN100 ~ 15 g/L 
GN118 Failed to lactate 
GN304 No detectable levels of HC and LC 
GN388 ~ 5-10 g/L 
GN451 ~ 3-5 g/L 
 
Chromosomal transgene integration in lines GN388 and GN451 
The transgene integration sites for both lines taken forward in this study were determined by whole genome 
next generation sequencing which revealed a single distinct chromosomal location for each transgenic line 
(Figures S3A-D). In line GN388, the transgenes were integrated into a single insertion site on chromosome 23 
at position 45,650,975 (CM004584.1) by replacing 22 bp of endogenous sequence (45,650,975-45,650,997). 
For line GN451 the transgene insertion site was found on chromosome 21 at position 26,329,477 
(CM004584.1). Mapping of the endogenous sequences flanking the breakpoints to the goat genome determined 
that in line GN388 and line GN451 the transgenes were inserted within the last intron of the longest isoform of 
the zinc finger protein 451 gene (ZNF451) and the first intron of the cell migration inducing hyaluronan binding 
protein gene (CEMIP), respectively. The breakpoints were verified by PCR and sequencing of the PCR 
products (Figure 3). This confirmed both breakpoints in line GN388 with the 5’-end of a partial transgene copy 
at one side and the 3’-end of the HC-transgene at the other breakpoint. For line GN451, only one of the 
insertion breakpoints could be determined by PCR because of the presence of a repetitive sequence in the 
genomic region at the other side. At the identified breakpoint, the endogenous genomic sequence was 
juxtaposed to the 3’ terminal end of a transgene copy. PCR amplification between the endogenous locus and the 
puromycin selection marker verified the breakpoint and identified that the 3’ end of the HC-transgene was 
present at the breakpoint.  
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Fig. 3. Transgene insertion sites. A) schematic representation of the functional elements of the LC- and HC- 
transgenes. 5’CN, 3’CN: gCSN2 5’ and 3’ regulatory sequences; HC, LC: heavy and light chain encoding 
sequences; puro: puromycin selection marker; black arrowheads: chicken β-globin insulators. B) schematic 
outline of the transgene insertions in line GN388. The transgenes at the breakpoints (BP1, BP2) of the 
endogenous locus are depicted. The corresponding endogenous (black) and transgene sequences (highlighted in 
dark blue) at the breakpoints are shown below the insertion site outline. x TG copies: cluster of additional 
transgene copies. C) schematic outline of the transgene insertions in line GN451. The sequence of the junction 
between endogenous locus and transgene sequences (highlighted in blue) are shown for BP1. Location of PCR 
primers for amplification of the breakpoint junctions are indicated. 
 
The next generation sequence data were also used to enumerate the number of transgene copies. From this 
analysis, we determined that line GN388 carried a total of seven to eight transgene copies comprised of two LC- 
and five HC-transgenes based on the mate pair library sequence data (Table S2A). Results with the paired end 
library were less consistent with 10-11 transgenes in total, comprised of one LC- and three HC-transgene 
copies. Line GN451 had a total of two transgene copies consisting of one LC- and one HC-transgene (Table 
S2B).  
 
Next, we used REF to visually verify the integrity of the coding regions of the LC- and HC-transgene copies. 
For the transgenes in line GN451, the minimum coverage was 2 reads with an average coverage of 5.2 (paired 
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end) and 6.5 (mate pair) for the LC-transgene and 4.2 (paired end) and 9.2 (mate pair) for the HC-transgene. 
Only reads with a mapping quality of 30 and a base call quality of 30 were considered, verifying the integrity of 
both single copy genes. For line GN388, the minimum coverage for the LC and HC transgenes was 17 and 30 
for the paired-end library and 7 and 12 for the mate pair library, respectively giving an expected minimum 
coverage of any transgene copy of 2 per library and 8 when both libraries were combined. Using the binomial 
distribution, this gives a 1 in 14 and 1 in 800 chance, respectively, of an individual transgene copy not being 
represented in the worst case. No mutations or insertions were detected and there was relatively even coverage 
along the transgenes in both sequencing library types, indicating the coding regions of all copies of both LC- 
and HC-transgenes were intact in both transgenic lines (Figure S4).  
 
Stability of genotype 
Stability of integration was demonstrated via transmission of the intact transgenes through to subsequent 
generations. PCR-amplification and sequencing of the breakpoints from the founders, F1 and F2 animals were 
performed for both transgenic lines. The amplified fragment size and sequences of the breakpoints in the 
offspring were identical to those of the founder animals for each of the respective transgenic lines (Figure S5). 
 
Southern analysis (Figure 4A) and ddPCR assays (Figure 4B) were subsequently performed to determine 
whether the number of transgene copies remained stable or were subject to change in subsequent generations. 
Results from both methods were consistent and determined the same number of transgene copies for the two 
transgenic lines which were also in accordance with the sequence-based copy number results. For the founder 
goat from line GN388, we detected two light chain and five heavy chain transgene copies and one copy each of 
light chain and heavy chain for the founder goat from line GN451. F1 and F2 offspring from both founder 
transgenic lines, as well as F3 offspring from the transgenic line GN388, maintained the transgene copies 
present in the founders which confirmed stable inheritance and constancy of the transgenic genotype.  
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Fig. 4. Transgene copy number determination in multiple generations. A) Assessment of transgene insertions by 
Southern analysis. Shown are the results for the founders (F0), two F1 (F1-1, F1-2), two F2 (F2-1, F2-2) and 
two F3 (F3-1, F3-2) offspring for the transgenic lines GN388 and GN451 as indicated. WT: non-transgenic wild 
type control; MW: molecular weight marker; WT+LC: wild type genomic DNA spiked with the equivalent of 2 
LC copies; WT+HC: wild type genomic DNA spiked with the equivalent of 2 HC copies; CN: signal from the 
endogenous gCSN2 copies; HC: signal of the heavy chain encoding transgene; LC: signal of the light chain 
encoding transgene. Quantitation results for the LC and HC transgene copies are summarized in the table below 
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the Southern blot. B) Analysis by ddPCR. Shown are representative 2D-plots (channel 1 FAM-target vs channel 
2 Hex-reference) for the ddPCR copy number variation assay results for the LC- and HC-transgenes in lines 
GN388 and GN451. Grey droplets: double negative (no DNA); blue droplets: LC/HC positive, green droplets: 
LGB reference positive; orange droplets: double positive for LC/HC and LGB. Tables below the 2D-plots 
summarize the calculated transgene copy numbers for the F0-F3 generations as indicated. 
 
gCetuximab expression levels in milk 
To investigate consistency of the gCetuximab expression phenotype, we analyzed several goats. Daily lactation 
volumes of natural milk samples produced by F1 and F2 females from the transgenic line GN388 are presented 




Fig. 5. Milk yields of F1 and F2 generation goats. A) Daily natural lactation milk yields for different F1 and F2 
goats of line GN388. B) Depicts natural daily milk yields for the F1-2 goat, line GN451. Please note the 
different scales for A and B. 
 
The gCetuximab expression levels in milk were assessed by western blot and by calculation based on the 
gCetuximab yields determined according to our purification protocols. These estimates show similar 
gCetuximab production levels in the milk of the founders compared to their offspring with approximately 5-10 
g/L for line GN388 and 3-5 g/L for line GN451 (Table 4). 
 
Table 4. Estimated expression levels of goats from lines GN388 and GN451. 
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Line Goat gCetuximab 
(mg/mL) 
GN388 F0 5a, 10b 
 F1-1 9b 
 F2-1 7b 
GN451 F0 5a, 3a 
 F1-1 3b 
 F1-2 3b 
a  Estimate from western blot 
b Estimate from purification based on yield and milk volumes. 
 
gCetuximab purification 
gCetuximab was purified from milk samples produced by a founder goat of transgenic line GN100 (GN100, 
F0), and F1 goats for lines GN388 (GN388, F1) and GN451 (GN451, F1) using a two-step column 
chromatography strategy, comprising affinity and anion exchange separation principles. Purification from a 100 
mL milk sample processed for line GN100 yielded a total of 850 mg gCetuximab. For lines GN451 and GN388, 
25 mL of milk were processed for gCetuximab purification which yielded 55 mg and 150 mg purified antibody. 
The antibody preparations were then used for subsequent studies to further characterise the properties of 
gCetuximab. 
 
Glycosylation of gCetuximab 
Glycosylation of cetuximab when produced in the goat mammary gland or in the mouse cell line will not be 
identical. Such differences could enhance the functionality of gCetuximab compared to Erbitux and provide 
evidence that the milk expession system could offer advantages to existing modalities of monoclonal antibody 
production. 
Cetuximab carries an N-linked glycosylation site at aa 88, in the variable region of the heavy chain. The bi-
antennary sugar moiety on this site has been found to carry α-Gal, when the commercial antibody Erbitux is 
produced in the Sp2/0 mouse cell line (25). This sugar modification is undesirable because it is highly 
immunogenic and has been shown to be responsible for adverse immune reactions following treatment with 
Erbitux (14). To investigate whether the antibody is modified by α-Gal when produced in the mammary gland 
of goats, purified gCetuximab derived from goat lines GN100, and GN388 was analyzed. Their glycosylation 
patterns were compared to commercially obtained Erbitux. Results shown in Figure 6 confirmed the presence of 
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α-Gal in the commercial product and more importantly, absence of the α-Gal modification on the mAb 




Fig. 6. HPLC analysis of α -Gal on commercial and gCetuximab 
Chromatograms above show the release of α -Gal when treated with α -galactosidase A. Red traces show 
protein samples treated with α -galactosidase A, and blue traces are samples without added enzyme. Arrows 
indicate the position of the α -Gal peak, which elutes from the column at approximately 19.5 min. A) Laminin, a 
protein known to contain α -Gal; B) commercially sourced Erbitux; C) purified gCetuximab sample from the 
founder of line GN388; D) purified gCetuximab sample from the founder of line GN100. 
 
In order to further confirm the lack of α-Gal on gCetuximab, western blot analysis was performed using a 
detecting antibody specific to the α-Gal moiety. Purified samples of the milk-produced gCetuximab and 
commerical Erbitux were tested for the presence of the α-Gal marker. Positive signals were detected on 
commercial Erbitux and goat serum (Figure S6). Since the goat adds α-Gal to serum proteins, it confirms the 
ability of the detecting antibody to identify the moiety. As can be seen, however, there are no signals indicating 
the presence of α-Gal in the purified gCentuximab (Figure S6). This corroborates the LC/MS results 
demonstrating that although the goat has the ability to add α-Gal and does so for serum proteins, goats do not 
decorate gCetuximab produced in the mammary gland and secreted into the milk. 
 
In addition to the α-Gal modification, the gCetuximab samples were analyzed for sugar configurations. From 
the LC/MS data, the amounts of galactose (Gal) and afucosylated core sugars were calculated. As shown in the 
summary Table 5, the GN451 sample carried a higher level of afucosylated sugar, which has been correlated to 
increased CD16 binding and ADCC activity (26). In addition, increased galatose levels have also been 
correlated to increases in CD16 binding and ADCC activity, though to a lesser degree (27). This prompted us to 
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further investigate CD16 binding and ADCC activity of gCetuximab. It should be noted that two of three goats 
from the GN388 line produced antibody with high levels of afucosylated antibody. Such variability has been 
observed and is attributed to variable genetics of the particular milking animal (data not shown).   
 




Gal/moleb % afucosylated 
gCetuximab GN100, F0  185  (92%) 7.4 8 
gCetuximab GN388, F0 161  (81%) 6.5 17 
gCetuximab GN388, F1-1 151  (76%) 6.0 6 
gCetuximab GN388, F2-1 159  (80%) 6.4 17 
gCetuximab GN451, F1-1 129  (65%) 5.2 16 
gCetuximab GN451, F1-2  126  (63%) 5.0 22 
Erbitux Commercial 131  (66%) 5.3 6 
a Relative galactosylation is the sum of the percentage of each carbohydrate structure in the sample multipled by 
the number of gal residues in that structure. Since each structure can have one or two gal residues this value can 
be a maximum of 200. Dividing this number by two gives the percent galactosylation. 
b Gal/mole is calculated by multiplying the percent galactosylation by eight, the maximum possible number of 
Gal residues per molecule.  
 
Binding to EGFR on HTB-30 cells 
To be useful as a therapeutic, it was necessary to show that gCetuximab would bind to the intended target 
EGFR with similar efficiency as Erbitux. A study was performed by comparing the binding of Erbitux and goat-
produced antibody to HTB-30 cells, a human breast cancer cell line known to express both EGFR and Her-2 
antigens (28). For this assay, serial dilutions of fluorescently labelled antibody were applied to cells and binding 
to EGFR determined by measuring cell-bound fluorescence. Plotting of the mean fluorescent intensity (MFI) 
values confirmed that gCetuximab and Erbitux have very similar binding efficiencies (Fig. 7A). 
 
Enhanced CD16 binding and improved ADCC 
Cetuximab is known to recruit cytotoxic effector immune cells against tumor cells expressing EGFR, resulting 
in ADCC. To examine whether gCetuximab might exhibit increased ADCC compared to Erbitux we first 
determined each protein’s ability to bind to CD16, a crucial receptor involved in ADCC. gCetuximab purified 
from the three different milk samples (GN100, F1; GN388, F1-1; GN451, F1-2) were tested for CD16 binding 
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in competition with a fluorescently labelled antibody. In this assay high fluorescence from high levels of bound 
competitor indicates low CD16 binding affinity of the tested antibody and conversely, low fluorescence levels a 
high CD16 binding affinity. MFI values for the three goat-produced antibodies (25.1, 28.1 and 21.8) were lower 
than for Erbitux (32.4). Binding to CD16 was calibrated against known antibodies with low (Rituxan) and high 
(R297) CD16 binding affinity with their MFI 41.5 and 7.3 arbitrarily set at 0% and 100% CD16 binding, 
respectively. All three batches of gCetuximab showed enhanced binding to CD16 (39.3 % – 57.7 %) compared 




Fig. 7. Comparative binding efficiencies of gCetuximab and Erbitux to EGFR and CD16 and their potential for 
enhanced ADCC. A) Binding efficiency of gCetuximab (black) and Erbitux (red) to EGFR was assessed using 
flow cytometry by binding serial dilutions of antibody (as indicated) to EGFR-expressing HTB-30 cells. Shown 
are MFI measurements plotted against antibody concentration to determine binding efficiency. B) CD16 
binding on Jurkat-CD16-cells for 3 different batches of gCetuximab produced by F0 and F1 goats from different 
transgenic lines (black, as indicated), compared to commercial Erbitux (red). The MFI observed are expressed 
in percent of CD16 binding, with 100% being the value obtained with the R297 anti-D mAb (EMABling, LFB; 
blue) and 0% the value in the presence of Rituxan. C) Anti-EGFR antibody-bound target cell mediated IL-2 
secretion from activated Jurkat-CD16 cells. Shown are the results of two independent measurements of the IL-2 
levels in cell culture supernatants for co-cultures of Hep-2 cells incubated with the indicated concentrations of 
antibodies in the presence of Jurkat-CD16 cells. Unrelated antibody (blue): mAb that does not recognize EGFR; 
Erbitux (red): commercial cetuximab; gCetuximab (black): purified from F1-2, line GN451. 
 
Next, an ADCC bioassay was utilized based on the activation of Jurkat-CD16 cells by antibody-bound target 
cells. For the assay, Hep-2 cells were utilized as suitable target cells after confirming expression of EGFR on 
their cell surface (Figure S8).  
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In the presence of Jurkat-CD16 cells, Hep-2 target cells mediated interleukin-2 (IL-2) secretion from Jurkat-
CD16 cells dependent on their anti-EGFR antibody loading (Figure 7C). IL-2 secretion with gCetuximab, 
purified from F1-2 of line GN451, had a maximal efficacy (Emax) of 127 (±7.8) pg IL-2/mL and a half 
maximal effective concentration (EC50) of 10 ng/mL for gCetuximab. The equivalent IL-2 secretion mediated 
by commercial Erbitux was much lower with an Emax value of only 20 (±2.1) pg IL-2/mL. Due to the low 
secretion levels, we were unable to determine the EC50 value for Erbitux. 
 
DISCUSSION 
Dairy animals represent an attractive alternative production platform for therapeutic proteins compared to 
prevailing mammalian culture systems. However, only two therapeutic proteins isolated from the milk of 
transgenic animals have so far entered the marketplace (7-9). They were recently joined by a third product, 
human coagulation factor VII, that has now gained approval by the FDA (11). 
There are a growing number of efficacious mAbs, and the need for large amounts of such therapeutic mAbs for 
the treatment of serious human diseases. This makes mAbs ideal candidates for production in transgenic dairy 
animals due to their ability for flexible, economic production of large amounts of mAbs in milk (6, 12, 29) 
Described here are the first steps to developing an alternative to traditional production of  commercial mAbs 
such as Erbitux. Evidence is presented that stable lines of founder transgenic animals can be obtained that 
produce high levels of recombinant mAb in their milk. These lines of animals carry transgenes that are stably 
integrated and were shown to be free of any unwanted mutations. 
Next generation sequencing enabled the identification of the chromosomal insertion sites which allowed the 
confirmation of stable transmission of the transgene copies into the next generation. Hence, conventional 
breeding approaches can be readily applied for the large scale expansion of the mAb-producing goat lines for 
commercial gCetuximab production. However, we observed that not all transgenic lines were suitable for large-
scale production. Goat lines with integrations of many transgene copies failed to properly lactate, most likely 
due to high transgene expression levels that might have interfered with the efficient secretion of the mAb and 
other components naturally found in milk. By contrast, low copy lines with between one and four copies of the 
LC- and HC-transgenes lactated normally. Overall, no other phenotype was observed, and all goats were 
healthy. 
The high level of production of 5-15g/L compares with the expression level of an anti-CD20 mAb in cattle (12). 
With the expected goat milk yield of 800L/year, these animals can easily produce multiple kilograms of 
gCetuximab annually. The mAb is readily accessible in the milk and, as shown in our study, can be efficiently 
purified, fulfilling an important prerequisite for commercial production. 
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The monoclonal produced, gCetuximab, has the required equivalent capabilities as the innovator product, 
Erbitux. Critically, it binds to the EGFR found on tumor cells with comparable affinity to the commercial 
product and can be efficiently purified, necessary for commercial production.  
Significantly, the goat-produced mAb, gCetuximab, has two distinct advantages over the current Erbitux 
product.  First of all, the goat mammary gland does not modify gCetuximab with the highly immunogenic α-Gal 
epitope. By contrast, α-Gal is present on the current Erbitux product which has been shown to elicit an adverse 
response in some patients triggered by an immune reaction against α-Gal (14). This would increase the safety 
profile of treatments with gCetuximab compared to Erbitux. 
Secondly, evidence is provided that gCetuximab has increased effectiveness compared to the current Erbitux 
product. The mechanism of action of Erbitux is believed to be primarily through interference of the binding of 
EGF to the extracellular domain of the EGFR, blocking dimerization and activation of the receptor (30-32). 
ADCC could provide a mechanism to enhance the effectiveness of Erbitux but has not been exploited. This 
capability of ADCC has recently been recognized by glycoengineering cetuximab for a tighter binding to CD16 
associated with increased ADCC (33).  The fact that the gCetuximab samples show increased binding to CD16 
suggests that they have increased ADCC activity. This was then directly demonstrated with mAbs produced by 
the goat line GN451, which had the highest CD16 binding affinity. ADCC acitivity of the gCetuximab samples 
showed a more than six-fold increase compared to the commercial product.  
In a separate study, detailed comparative characterisation of gCetuximab vs Erbitux, including in vitro and in 
vivo assessments of EGFR inhibition and anti-tumour effects further demonstrated that gCetuximab has the 
required equivalent capabilities as the innovator product, Erbitux (34). 
Taken together, this suggests that gCetuximab not only has similar functionality but could also provide a more 
effective treatment option compared to Erbitux. Thus, the generation of these lines of animals, capable of high 
level production, could provide a a cost-effective source of a new and improved version of cetuximab, one 
without the α-Gal issue as well as increased effectiveness due to enhanced ADCC. 
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